Prospect Venture Partners

Managing Director Russell Hirsch leads investment decisions, drawing on experience as a General Partner at Mayfield and a research career at UCSF. The partnership includes David Schnell and was historically shaped by the late Alex Barkas. The firm's small-team structure concentrates decision-making among a few senior partners.

Prospect deploys across the full company lifecycle, from seed-stage formation through late-stage expansion rounds. The firm's own materials describe support for companies 'from seed to growth stage,' and its record includes incubations, early venture rounds, and board seats at publicly traded portfolio companies.

Prospect's partners combine academic research backgrounds with company-creation track records. Russell Hirsch conducted hepatitis B research published in Nature before moving to venture capital, and he personally incubated Intuitive Surgical and Millennium Pharmaceuticals. This operator-scientist identity shapes a model built on origination and active board service rather than passive fund commitments.

Available information points to direct company investments rather than fund-of-funds activity. The firm's website emphasizes partnership with management teams and active participation in building companies, without reference to investing in other venture funds.

Prospect focuses on life sciences broadly — biotechnology, medical devices, and healthcare technology. Disclosed board relationships span surgical robotics, cardiovascular devices, oncology, and orthopedics. The firm has not publicly disclosed any investments outside biomedical sectors.